文献速递口腔修复与种植

Sdccag3在高脂血症中促进种植体骨结合

Sdccag3 Promotes Implant Osseointegration during Experimental Hyperlipidemia.
PubMed 文献 · J Dent Res · 2020-04-27

本研究在高脂血症大鼠模型中探究Sdccag3对种植体骨结合的作用。研究发现高脂血症下Sdccag3和lncRNA-MSTRG.97162.4下调而miR-193a-3p上调;过表达Sdccag3或lncRNA-MSTRG.97162.4可改善骨结合指标,而过表达miR-193a-3p则损害骨结合。

要点

  • 高脂血症下调Sdccag3和lncRNA-MSTRG.97162.4,上调miR-193a-3p。
  • 过表达Sdccag3增加BV/TV(1.24倍)和BIC%(1.26倍)。
  • miR-193a-3p过表达降低BV/TV(0.86倍)和BIC%(0.82倍)。

核心结论

  • Sdccag3通过结合lncRNA-MSTRG.97162.4促进高脂血症条件下的种植体骨结合。

研究设计与样本

  • 采用高脂血症大鼠模型,对种植体周围0.5 mm区域骨组织进行微阵列和RNA测序分析。

主要发现

  • 高脂血症下调Sdccag3和lncRNA-MSTRG.97162.4,上调miR-193a-3p。
  • Sdccag3过表达使BV/TV增加1.24倍,BIC%增加1.26倍。
  • lncRNA-MSTRG.97162.4过表达使Sdccag3表达增加2.78倍,BV/TV增加1.45倍,BIC%增加1.07倍。
  • miR-193a-3p过表达抑制lncRNA-MSTRG.97162.4(0.63倍)和Sdccag3(0.88倍),BV/TV为0.86倍,BIC%为0.82倍。
  • miR-193a-3p下调则lncRNA-MSTRG.97162.4增加10.69倍,Sdccag3增加6.96倍,BV/TV增加1.20倍,BIC%增加1.26倍。

临床怎么用

  • Sdccag3及其相关lncRNA-MSTRG.97162.4和miR-193a-3p可能成为提高高脂血症患者牙种植成功率的治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperlipidemia adversely affects bone metabolism, often resulting in compromised osseointegration and implant loss. In addition, genetic networks associated with osseointegration have been proposed. Serologically defined colon cancer antigen 3 (Sdccag3) is a novel endosomal protein that functions in actin cytoskeleton remodeling, protein trafficking and secretion, cytokinesis, and apoptosis, but its roles in the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and in implant osseointegration under hyperlipidemic conditions have not been uncovered. Here, we performed microarray and RNA sequencing analysis to determine the differential expression of the Sdccag3 gene and related noncoding RNAs (ncRNAs) and to assess the long noncoding RNA (lncRNA) MSTRG.97162.4-miR-193a-3p-Sdccag3 coexpression network in bone tissues within the region 0.5 mm around implants in hyperlipidemic rats. In this experiment, we found that Sdccag3 and the previously uncharacterized lncRNA-MSTRG.97162.4 were downregulated during hyperlipidemia, while miR-193a-3p was upregulated. Sdccag3 overexpression increased new trabecular formation, the bone volume/total volume (BV/TV) (1.24-fold), and bone-implant combination ratio (BIC%) (1.26-fold). An RNA pulldown experiment revealed that Sdccag3 protein targeted lncRNA-MSTRG.97162.4 nucleotides 361 to 389. In addition, lncRNA-MSTRG.97162.4 overexpression significantly enhanced Sdccag3 (2.78-fold) expression and increased BV/TV (1.45-fold) and BIC% (1.07-fold) at the bone-implant interface. Taken together, these findings indicate that Sdccag3 overexpression enhances implant osseointegration under hyperlipidemic conditions by binding to lncRNA-MSTRG.97162.4. Furthermore, miR-193a-3p overexpression inhibited lncRNA-MSTRG.97162.4 (0.63-fold) and Sdccag3 (0.88-fold) expression and induced poor implant osseointegration (BV/TV, 0.86-fold; BIC%, 0.82-fold), while miR-193a-3p downregulation produced the opposite results (lncRNA-MSTRG.97162.4, 10.69-fold; Sdccag3, 6.96-fold; BV/TV, 1.20-fold; BIC%, 1.26-fold). Therefore, our findings show that Sdccag3 promotes implant osseointegration, and its related lncRNA-MSTRG.97162.4 and miR-193a-3p play an important role in osseointegration during hyperlipidemia, which might be a promising therapeutic target for improving dental implantation success rates.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Ren H, Huo F, Wang Z, et al. Sdccag3 Promotes Implant Osseointegration during Experimental Hyperlipidemia. J Dent Res. 2020. PMID: 32339468. doi:10.1177/0022034520916400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。